The life sciences sector continues to play an increasingly important role in improving healthcare while driving economic growth through scientific innovation. From breakthrough therapies and advanced medical devices to digital health technologies and precision diagnostics, the industry is developing solutions that have the potential to transform patient care worldwide. However, bringing these innovations from research laboratories to commercial markets requires long term investment, specialist expertise, and access to experienced healthcare investors. To strengthen this innovation ecosystem, the British Business Bank has announced a new commitment to one of Europe’s leading life sciences investment platforms.
The British Business Bank has committed €25 million to the EQT Health Economics 3 Fund, a multi stage investment fund managed by EQT Life Sciences that focuses exclusively on life sciences, medical technology, diagnostics, therapeutics, and health technology companies.
The investment reflects the Bank’s ongoing strategy to support the growth of innovative healthcare businesses while strengthening the United Kingdom’s position as a global centre for life sciences.
Supporting Healthcare Innovation
EQT Life Sciences has built a long history of investing in companies developing innovative healthcare technologies.
Over the past three decades, the investment firm has raised more than €3.7 billion across 13 private investment funds while supporting over 150 companies through various stages of development.
Its portfolio spans a broad range of healthcare sectors including therapeutics, medical devices, diagnostics, and digital health solutions.
The firm works closely with entrepreneurs and management teams, helping companies progress from early clinical development through regulatory milestones and commercial expansion.
Its investment approach combines financial backing with operational expertise tailored to the healthcare industry.
Focus on Commercial Stage Companies
The EQT Health Economics 3 Fund is designed to invest in commercial stage healthcare companies that have already reduced many of the scientific and development risks typically associated with early stage innovation.
The fund focuses particularly on medical technology and digital health businesses developing products capable of improving healthcare delivery and patient outcomes.
By supporting companies that are closer to commercial adoption, the fund aims to accelerate the availability of innovative healthcare solutions while helping businesses scale internationally.
This strategy complements broader efforts to strengthen healthcare innovation across Europe and the United Kingdom.
Building on an Existing Partnership
The latest commitment also expands an established relationship between the British Business Bank and EQT Life Sciences.
The two organisations have previously collaborated through co investments in UK healthcare companies including Phagenesis and Cyted Health.
These investments demonstrate a shared commitment to supporting promising health technology businesses with both financial resources and specialist expertise.
The continued partnership is expected to create additional opportunities for innovative UK companies seeking growth capital and international investment support.
Strengthening the UK Life Sciences Ecosystem
The British Business Bank views life sciences as one of the country’s most strategically important growth sectors.
By investing in experienced international venture funds, the organisation aims to attract additional private capital into the UK while helping domestic companies access global networks and specialist healthcare investors.
The strategy supports businesses developing technologies that can improve patient care, strengthen healthcare systems, and contribute to economic growth through scientific innovation.
Increasing access to experienced investors also helps companies navigate complex regulatory, clinical, and commercial development pathways.
Supporting Future Healthcare Growth
The new €25 million commitment is expected to strengthen EQT Life Sciences’ ability to continue investing in innovative healthcare companies across therapeutics, diagnostics, medical devices, and digital health.
At the same time, the investment reinforces the British Business Bank’s broader objective of supporting high growth businesses operating in strategically important sectors of the UK economy.
As demand for innovative healthcare solutions continues to increase worldwide, access to specialist capital remains essential for transforming scientific discoveries into commercially successful products. Through this latest investment, both organisations aim to support the continued growth of life sciences companies capable of delivering meaningful advances in healthcare while strengthening the United Kingdom’s position as a leading destination for health innovation.
